Keywords: Teva, USA, Drug pricing, Law suits, Financial
Teva makes settlement in certain US drug pricing law suits, leading to 4th quarter charge of $315 million
Article | 8 February 2010
Israel-headquartered Teva Pharmaceutical Industries says that several of its subsidiaries in the USA have reached a settlement in principle to resolve claims brought by Ven-A-Care of the Florida Keys on behalf of the US states Texas, Florida and California under federal and state False Claims Acts.
Together with many other pharmaceutical manufacturers, Teva is named in numerous civil law suits that relate to drug price reporting by manufacturers in about 15 states. Enjoying this article? To continue reading you need to login, take a FREE trial or subscribe.
FREE unlimited, no obligation access to The Pharma Letter website for 30 days, normally worth £60!
Sign up in less than 60 seconds...no payment needed
Want to read the full article?
Take a 30 day FREE Trial worth £60
Take a no obligations 30 day trial.
Only one trial per user. Find out more details
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Pfizer acts to stop Mylan marketing generic Chantix; Allergan in $600 million settlement over Botox marketing practices
- PDL BioPharma sues Roche’s Genentech over royalties
- Novartis/NIH-sponsored research yields promising malaria drug candidate
- Indian’s Ranbaxy inaugurates new $30 million drug manufacturing facility in South Africa
- Seattle Genetics gets milestone as Astellas unit moves cancer drug into Ph I
